DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for eosinophilic gastroenteritis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEosinophilic gastroenteritis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for eosinophilic gastroenteritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 13 (IL13) — IL13 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3LB6 · 3.05 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No medication is approved by the US Food and Drug Administration for eosinophilic gastroenteritis. Treatment remains empirical, based on symptom severity and clinician experience. Mild disease may be managed symptomatically; more severe cases or those with malabsorption require aggressive therapy. Options tried include dietary treatment, glucocorticosteroids, leukotriene receptor inhibitors, mast cell stabilisers, immunomodulating drugs, and biological drugs. A short course of corticosteroids is described as the treatment of choice in a 2018 case series of three patients.
The disease is rare, which limits experience with management options and prevents randomised controlled trials that could clearly delineate efficacy of new agents. A 2022 review states there is still a lack of well-designed, prospective, randomised clinical trials involving large groups of patients. The same review notes that more research is needed to compare efficacy and safety profiles of available treatments and to select prognostic factors for relapse, which would inform decisions about initial treatment and maintenance therapy.
A 2024 case report describes a 23-year-old male with recurrent abdominal pain and loose stools treated with antibiotics and antispasmodics, with no history of substance abuse, prior surgeries, comorbidities, skin allergies, breathing difficulties, or recurrent infections. The 2018 case series notes that patients may or may not have peripheral eosinophilia and that the disease has a chronic clinical course.
What is still missing are adequately funded, prospective, randomised trials enrolling sufficient numbers of patients to compare treatments head-to-head, and validated prognostic factors to stratify patients by relapse risk.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Scandinavian Journal of Gastroenterology · 2015 · 16 citations
The management of eosinophilic gastroenteritis
AbstractEosinophilic gastroenteritis (EG) is a rare disorder characterized by eosinophilic infiltration of the gastrointestinal tract. No medication at present is approved by the Food and drug administration of United States for the treatment of EG. The rarity of the disease limits our experience with the different management options. It also limits the ability to conduct randomized controlled trials that could clearly delineate the efficacy of new therapeutic agents. This review assesses the various management options that have been tried on patients with EG.
Gastroenterology Review · 2022 · 1 citations · open access
Eosinophilic gastroenteritis – a manifestation of an allergic disease in the gastrointestinal tract? Part 2. Treatment
AbstractTreatment of eosinophilic gastroenteritis (EGE) is mainly empirical and is based on the assessment of symptom severity and the experience of clinicians. Patients with mild disease can be treated symptomatically, while patients with more severe symptoms or malabsorption symptoms require more aggressive therapy. So far, several therapeutic options have been proposed, including the following: dietary treatment, glucocorticosteroids, inhibitors of leukotriene receptors, mast cell stabilizers, immunomodulating drugs, and biological drugs. Unfortunately, there is still a lack of well-designed, prospective. and randomized clinical trials involving large groups of patients with EGE and assessing the effectiveness of individual treatments. More research is needed to compare the efficacy and safety profiles of the various treatments available, and to select the prognostic factors of relapse, which in turn will be extremely important in making decisions about the initial treatment phase and maintenance therapy.
Journal of Digestive Endoscopy · 2024 · 0 citations · open access
A Rare Case of Eosinophilic Gastroenteritis Presenting as Ascites
AbstractEosinophilic gastroenteritis is a rare disorder of unknown cause characterized by focal or diffuse eosinophilic infiltration of gastrointestinal tract, especially the stomach and duodenum. A 23-year-old male with history of recurrent abdominal pain, loose stools since 2 weeks, and treated with antibiotics and antispasmodics with no history of substance abuse, prior surgeries, comorbidities, skin allergies, breathing difficulties, recurrent infections.
Gastroenterology & Hepatology International Journal · 2018 · 0 citations · open access
Eosinophilic Gastroenteritis: 3 Cases and Review of Literature
AbstractEosinophilic Gastroenteritis: Eosinophilic Gastroenteritis (EGE) is a rare disease affecting one or more segments of gastrointestinal tract, mainly stomach and small bowel with dense eosinophilic infiltration in gastrointestinal tract. It has a chronic clinical course. The patients may or may not have peripheral eosinophilia. The treatment of choice is a short course of corticosteroids. We present three cases of eosinophilic gastroenteritis with review of literature
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
